**Current Lung-MAP Schema**

*LUNGMAP screening protocol (activated 1/28/19) allows all histologic types of NSCLC. S1400, the original screening/umbrella protocol included only squamous lung cancer. S1400 accrued patients between 6/16/2014 and 1/28/2019. While S1400 is closed to accrual, patients enrolled to S1400 may participate in sub-studies they are eligible for.

**TRIAL POINTS OF INTEREST:**
- Each of sub-study operates independently of the others
- Prescreening can be performed while the patient is on any line of therapy for stage IV disease
- Repeat or fresh biopsy necessary for tissue screening is paid by the trial
- Biomarker-driven sub-studies may progress to Phase III if study meets endpoint and Phase III is feasible, at which point the standard of care arm will be determined

---

**S1400B**: PI3K+ Taselisib

**S1400C**: CCGA+ Palbociclib

**S1400D**: FGFR+ AZD4547

**S1400E**: c-MET+ Rilotumumab+Erlotinib

**S1400F**: HRRD+ Talazoparib

**S1400G**: c-MET+ Teliso-V (ABBV-399)

**S1400H**: Pembrolizumab+ Ramucirumab vs. SoC

**S1800A**: Checkpoint Refractory

**S1900A**: LOH/BRCA+

**S1900B**: STK11+ RET fus +

**S1900C**: TAK228 + docetaxel vs. SoC

**S1900D**: NFE2L2/KEAP1+

**S1900E**: KRAS+ TP53, LKB1/STK11

**S1900F**: Durvalumab + Tremelimumab (both cohorts)

**S1900G**: Pembrolizumab vs. SoC

**S1900H**: Open

**S1900I**: Closed/Closed